Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatinGIOVANNETTI, E; ZUCALI, P. A; RONCALLI, M et al.British journal of cancer. 2011, Vol 105, Num 10, pp 1542-1553, issn 0007-0920, 12 p.Article

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesotheliomaCERESOLI, G. L; ZUCALI, P. A; SOTO-PARRA, H et al.British journal of cancer. 2013, Vol 109, Num 3, pp 552-558, issn 0007-0920, 7 p.Article

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesotheliomaZUCALI, P. A; PERRINO, M; LORENZI, E et al.Lung cancer. 2014, Vol 84, Num 3, pp 265-270, issn 0169-5002, 6 p.Article